IMPAX TO PRESENT AT WALL STREET ANALYST FORUM INSTITUTIONAL INVESTOR CONFERENCE BUSINESS EDITORS/HEALTH & MEDICAL WRITERS HAYWARD, CALIF.--(BW HEALTHWIRE)--FEB. 12, 2001--IMPAX LABORATORIES INC.
HAYWARD, Calif.--(BW HealthWire)--Feb. 12, 2001--IMPAX
Laboratories Inc. (Nasdaq NM: IPXL.O) today announced that the Company
will present at the Wall Street Analyst Forum's Institutional Investor
Conference on Wednesday, February 14, 2001 at 1:50 p.m. (EST).
The conference will be held at The Roosevelt Hotel in New York and
attendees will include institutional money managers and analysts.
Barry R. Edwards, co-chief executive officer, Larry Hsu, president and
chief operating officer and Cornel C. Spiegler, CFO, will represent
the Company.
Individuals interested in listening to the presentation via the
Internet webcast may do so by visiting IMPAX's website
(www.impaxlabs.com). The audio will be archived on the site for 90
days following the conference.
IMPAX currently has eight Abbreviated New Drug Applications
pending at the U.S. Food and Drug Administration that address more
than $5.6 billion in U.S. branded product sales. Seven of these
filings were made under Paragraph IV of the Hatch-Waxman Amendments.
IMPAX Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and niche
generics in addition to the to the development of branded products.
IMPAX markets its generic products through its Global Pharmaceuticals
division and intends to market its branded products through the IMPAX
Pharmaceuticals division. IMPAX Laboratories is headquartered in
Hayward, California, and has a full range of capabilities in its
Hayward and Philadelphia facilities. For more information, please
visit the Company's Web site at www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act
To the extent any statements made in this news release contain
information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including
the difficulty ofpredicting FDA filings and approvals, acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, new product development and launch, reliance on
key strategic alliances, uncertainty of patent litigation filed
against us, availability of raw materials, the regulatory environment,
fluctuations in operating results and other risks detailed from time
to time in the Company's filings with the Securities and Exchange
Commission.
--30--db/ny*
CONTACT: Company Contacts:
IMPAX Laboratories, Inc.
Barry R. Edwards, 215/289-2220 Ext. 371
Co-CEO
Larry Hsu, 510/471-3600 Ext. 354
Ph.D. Pres. & COO
Cornel C. Spiegler, 215/289-2220 Ext.306
CFO
www.impaxlabs.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212/838-3777
kgolodetz@lhai.com
Bruce Voss, 310/691-7100
bvoss@lhai.com
www.lhai.com
KEYWORD: CALIFORNIA NEW YORK |
